NIH Researchers Develop New Opioid with Reduced Addiction Risk
Researchers at the National Institutes of Health (NIH) have developed a new opioid compound that offers strong pain relief without the typical risks of addiction and respiratory depression. This new compound, derived from a class of synthetic opioids known as nitazenes, was tested in laboratory animals and showed promising results. The study, published in Nature, highlights the compound's ability to provide effective pain relief while minimizing adverse effects commonly associated with opioids. The research team focused on modifying the nitazenes to retain their pain-relieving properties while reducing their potency to improve safety. The compound, referred to as DFNZ, demonstrated a safer pharmacological profile, avoiding respiratory depression and showing minimal withdrawal symptoms in preclinical tests. 
